7/18 BBA Session 2 – Biologic Product and Process Development
With seven of top ten global best-selling drugs in 2017 being biopharmaceuticals, it is estimated that by 2022 the global market for this drug category will reach US$326 billion. But with many of the earlier biologic drugs coming off patent one after another, huge opportunities are opening up for biosimilars companies to step in. Not only are some of the world's largest pharmaceutical companies competing to invest this industry space, many Taiwanese manufacturers are also rushing to build capability in this field.
Biologics development will be the focus of Session 2 of the three-day BioBusiness Asia conference, with the session entitled 'Biologics Product and Process Development'. The program will feature a number of influencers in this field, including Hu Wei-Shou, Ph.D., University of Minnesota, USA, with his presentation 'Novel Technologies for Bioprocess Development'. Hu has outstanding achievements in the fields of biotechnology and bioengineering, and in particular, has devoted himself to talent cultivation, setting up courses that have trained thousands of scientists and engineers in the biomedical fields over the last 30 years. Also invited to speak are general manager of EirGenix, Liu Lee-cheng and executives from IQVIA, Novo Nordisk, Amarex and other international pharmaceutical and biotech companies. Topics to be discussed include clinical trial design for biologics, FDA
regulatory trends, and bioprocess design.